Literature DB >> 28495386

Development of molecular tools based on the dopamine D3 receptor ligand FAUC 329 showing inhibiting effects on drug and food maintained behavior.

Anne Stößel1, Regine Brox1, Nirupam Purkayastha1, Harald Hübner1, Carsten Hocke2, Olaf Prante2, Peter Gmeiner3.   

Abstract

Dopamine D3 receptor-mediated networks have been associated with a wide range of neuropsychiatric diseases, drug addiction and food maintained behavior, which makes D3 a highly promising biological target. The previously described dopamine D3 receptor ligand FAUC 329 (1) showed protective effects against dopamine depletion in a MPTP mouse model of Parkinson's disease. We used the radioligand [18F]2, a [18F]fluoroethoxy substituted analog of the lead compound 1 as a molecular tool for visualization of D3-rich brain regions including the islands of Calleja. Furthermore, structural modifications are reported leading to the pyrimidylpiperazine derivatives 3 and 9 displaying superior subtype selectivity and preference over serotonergic receptors. Evaluation of the lead compound 1 on cocaine-seeking behavior in non-human primates showed a substantial reduction in cocaine self-administration behavior and food intake.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Autoradiography; Dopamine D(3) receptor; Drug maintained behavior; Fluorine-18; Food maintained behavior; Positron emission tomography (PET); Selective D(3) antagonist; Self-administration; Subtype selectivity

Mesh:

Substances:

Year:  2017        PMID: 28495386      PMCID: PMC5512454          DOI: 10.1016/j.bmc.2017.04.036

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  49 in total

1.  Dopaminergic reward system: a short integrative review.

Authors:  Oscar Arias-Carrión; Maria Stamelou; Eric Murillo-Rodríguez; Manuel Menéndez-González; Ernst Pöppel
Journal:  Int Arch Med       Date:  2010-10-06

2.  Interactive SAR studies: rational discovery of super-potent and highly selective dopamine D3 receptor antagonists and partial agonists.

Authors:  Laura Bettinetti; Karin Schlotter; Harald Hübner; Peter Gmeiner
Journal:  J Med Chem       Date:  2002-10-10       Impact factor: 7.446

3.  The effects of the dopamine D₃ receptor antagonist GSK598809 on attentional bias to palatable food cues in overweight and obese subjects.

Authors:  Pradeep J Nathan; Barry V O'Neill; Karin Mogg; Brendan P Bradley; John Beaver; Massimo Bani; Emilio Merlo-Pich; Paul C Fletcher; Bridget Swirski; Annelize Koch; Chris M Dodds; Edward T Bullmore
Journal:  Int J Neuropsychopharmacol       Date:  2011-07-12       Impact factor: 5.176

4.  Modification of cocaine self-administration by buspirone (buspar®): potential involvement of D3 and D4 dopamine receptors.

Authors:  Jack Bergman; Rebecca A Roof; Cheryse A Furman; Jennie L Conroy; Nancy K Mello; David R Sibley; Phil Skolnick
Journal:  Int J Neuropsychopharmacol       Date:  2012-07-25       Impact factor: 5.176

Review 5.  Recent advances in the search for D3- and D4-selective drugs: probes, models and candidates.

Authors:  Stefan Löber; Harald Hübner; Nuska Tschammer; Peter Gmeiner
Journal:  Trends Pharmacol Sci       Date:  2011-01-12       Impact factor: 14.819

6.  Dopamine D3 receptor mRNA and binding sites in human brain.

Authors:  B Landwehrmeyer; G Mengod; J M Palacios
Journal:  Brain Res Mol Brain Res       Date:  1993-04

Review 7.  Current perspectives on selective dopamine D(3) receptor antagonists as pharmacotherapeutics for addictions and related disorders.

Authors:  Christian A Heidbreder; Amy H Newman
Journal:  Ann N Y Acad Sci       Date:  2010-02       Impact factor: 5.691

8.  High-fat diet induced adiposity in mice with targeted disruption of the dopamine-3 receptor gene.

Authors:  John-Andrews McQuade; Stephen C Benoit; Ming Xu; Stephen C Woods; Randy J Seeley
Journal:  Behav Brain Res       Date:  2004-05-05       Impact factor: 3.332

9.  Attenuation of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) neurotoxicity by the novel selective dopamine D3-receptor partial agonist FAUC 329 predominantly in the nucleus accumbens of mice.

Authors:  Frank Boeckler; Andreas Leng; Anna Mura; Laura Bettinetti; Joram Feldon; Peter Gmeiner; Boris Ferger
Journal:  Biochem Pharmacol       Date:  2003-09-15       Impact factor: 5.858

10.  Design, synthesis, and structure-activity relationship studies of a series of [4-(4-carboxamidobutyl)]-1-arylpiperazines: insights into structural features contributing to dopamine D3 versus D2 receptor subtype selectivity.

Authors:  Subramaniam Ananthan; Surendra K Saini; Guangyan Zhou; Judith V Hobrath; Indira Padmalayam; Ling Zhai; J Robert Bostwick; Tamara Antonio; Maarten E A Reith; Shea McDowell; Eunie Cho; Leah McAleer; Michelle Taylor; Robert R Luedtke
Journal:  J Med Chem       Date:  2014-08-15       Impact factor: 7.446

View more
  3 in total

1.  The highly selective dopamine D3R antagonist, R-VK4-40 attenuates oxycodone reward and augments analgesia in rodents.

Authors:  Chloe J Jordan; Bree Humburg; Myra Rice; Guo-Hua Bi; Zhi-Bing You; Anver Basha Shaik; Jianjing Cao; Alessandro Bonifazi; Alexandra Gadiano; Rana Rais; Barbara Slusher; Amy Hauck Newman; Zheng-Xiong Xi
Journal:  Neuropharmacology       Date:  2019-04-08       Impact factor: 5.250

2.  Fluorescent ligands for dopamine D2/D3 receptors.

Authors:  Anni Allikalt; Nirupam Purkayastha; Khajidmaa Flad; Maximilian F Schmidt; Alina Tabor; Peter Gmeiner; Harald Hübner; Dorothee Weikert
Journal:  Sci Rep       Date:  2020-12-14       Impact factor: 4.379

Review 3.  Pyrazoles as Key Scaffolds for the Development of Fluorine-18-Labeled Radiotracers for Positron Emission Tomography (PET).

Authors:  Pedro M O Gomes; Artur M S Silva; Vera L M Silva
Journal:  Molecules       Date:  2020-04-09       Impact factor: 4.411

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.